Exametazime Pregnancy and Breastfeeding Warnings
Brand names: Ceretec, Drax Exametazime
Exametazime Pregnancy Warnings
FDA pregnancy category: C
Potential benefit should outweigh the potential risk.
Animal reproduction studies have not been conducted.
It is not known whether Tc99m exametazime can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity.
FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Exametazime Breastfeeding Warnings
The manufacturer recommends formula feedings for 60 hours following administration.
Breast-feeding is not recommended during use of exametazime.
Excreted into human milk: Yes (technetium Tc99m); unknown (exametazime)
Excreted into animal milk: Unknown
The effects in the nursing infant are unknown.
See also
References for pregnancy information
- Product Information. Ceretec (exametazime). GE Healthcare. 2012.
References for breastfeeding information
- Product Information. Ceretec (exametazime). GE Healthcare. 2012.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.